Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies

References

• Burkitt D, O’Connor GT. Malignant lymphoma in African children. I. A clinical syndrome. Cancer. 1961;14:258–269.
   PubMed Web of Science ®Google Scholar
• Evens AM, Danilov A, Jagadeesh D, et al. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood. 2021;137(3):374–386. doi:10.1182/blood.2020006926
   PubMed Web of Science ®Google Scholar
• Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002;13(8):1264–1274. doi:10.1093/annonc/mdf253
   PubMed Web of Science ®Google Scholar
• Minard-Colin V, Aupérin A, Pillon M, et al. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children. N Engl J Med. 2020;382(23):2207–2219. doi:10.1056/NEJMoa1915315
   PubMed Web of Science ®Google Scholar
• Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomised, controlled, open-label, Phase 3 trial. Lancet. 2016;387(10036):2402–2411. doi:10.1016/S0140-6736(15)01317-3
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369(20):1915–1925. doi:10.1056/NEJMoa1308392
   PubMed Web of Science ®Google Scholar
• Roschewski M, Dunleavy K, Abramson JS, et al. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. J Clin Oncol. 2020;38(22):2519–2529. doi:10.1200/JCO.20.00303
   PubMed Web of Science ®Google Scholar
• Gopal S, Gross TG. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa. Blood. 2018;132(3):254–263. doi:10.1182/blood-2018-04-844472
   PubMed Web of Science ®Google Scholar
• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid Neoplasms. Leukemia. 2022;36(7):1720–1748. doi:10.1038/s41375-022-01620-2
   PubMed Web of Science ®Google Scholar
• Hochberg J, El-Mallawany NK, Abla O. Adolescent and young adult non-Hodgkin lymphoma. Br J Haematol. 2016;173(4):637–650. doi:10.1111/bjh.14074
   PubMed Web of Science ®Google Scholar
• Chene A, Donati D, Orem J, et al. Endemic Burkitt’s lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus. Semin Cancer Biol. 2009;19(6):411–420. doi:10.1016/j.semcancer.2009.10.002
   PubMed Web of Science ®Google Scholar
• Goldman S, Cairo MS. Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults. Best Pract Res Clin Haematol. 2023;36(2):101463. doi:10.1016/j.beha.2023.101463
   PubMed Web of Science ®Google Scholar
• Atallah-Yunes SA, Murphy DJ, Noy A. HIV-associated Burkitt lymphoma. Lancet Haematol. 2020;7(8):e594–e600. doi:10.1016/S2352-3026(20)30126-5
   PubMed Web of Science ®Google Scholar
• Afify Z, Orjuela-Grimm M, Smith CM, et al. Burkitt lymphoma after solid-organ transplant: treatment and outcomes in the paediatric PTLD collaborative. Br J Haematol. 2023;200(3):297–305. doi:10.1111/bjh.18498
   PubMed Web of Science ®Google Scholar
• Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443–459. doi:10.3322/caac.21357
   PubMed Web of Science ®Google Scholar
• Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354(23):2431–2442. doi:10.1056/NEJMoa055759
   PubMed Web of Science ®Google Scholar
• Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44(12):1321–1325. doi:10.1038/ng.2468
   PubMed Web of Science ®Google Scholar
• Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490(7418):116–120. doi:10.1038/nature11378
   PubMed Web of Science ®Google Scholar
• Panea RI, Love CL, Shingleton JR, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood. 2019;134(19):1598–1607. doi:10.1182/blood.2019001880
   PubMed Web of Science ®Google Scholar
• Schmitz R, Ceribelli M, Pittaluga S, et al. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med. 2014;4(2):a014282. doi:10.1101/cshperspect.a014282
   PubMed Web of Science ®Google Scholar
• Grande BM, Gerhard DS, Jiang A, et al. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood. 2019;133(12):1313–1324. doi:10.1182/blood-2018-09-871418
   PubMed Web of Science ®Google Scholar
• Thomas N, Dreval K, Gerhard DS, et al. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma. Blood. 2023;141(8):904–916. doi:10.1182/blood.2022016534
   PubMed Web of Science ®Google Scholar
• Patte C, Auperin A, Gerrard M, et al., FAB/LMB96 International Study Committee. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109(7):2773–2780. doi:10.1182/blood-2006-07-036673
   PubMed Web of Science ®Google Scholar
• Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109(7):2736–2743. doi:10.1182/blood-2006-07-036665
   PubMed Web of Science ®Google Scholar
• Cairo MS, Sposto R, Gerrard M, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012;30(4):387–393. doi:10.1200/JCO.2010.33.3369
   PubMed Web of Science ®Google Scholar
• Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood. 1999;94(10):3294–3306.
   PubMed Web of Science ®Google Scholar
• Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105(3):948–958. doi:10.1182/blood-2004-03-0973
   PubMed Web of Science ®Google Scholar
• Goldman S, Barth M, Hochberg J, et al. Reduced burden of oncologic therapy in children, adolescents and young adults with good risk (GR) CD20 + mature B‐cell lymphoma. Br J Haematol. 2018;182(Suppl. 1):11.
   PubMedGoogle Scholar
• Diviné M, Casassus P, Koscielny S, et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol. 2005;16(12):1928–1935. doi:10.1093/annonc/mdi403
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Ludwig WD, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996;87(2):495–508.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Walewski J, Döhner H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014;124(26):3870–3879. doi:10.1182/blood-2014-03-563627
   PubMed Web of Science ®Google Scholar
• Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14(3):925–934. doi:10.1200/JCO.1996.14.3.925
   PubMed Web of Science ®Google Scholar
• Corazzelli G, Frigeri F, Russo F, et al. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B-cell lymphoma. Br J Haematol. 2012;156(2):234–244. doi:10.1111/j.1365-2141.2011.08947.x
   PubMed Web of Science ®Google Scholar
• Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106(7):1569–1580. doi:10.1002/cncr.21776
   PubMed Web of Science ®Google Scholar
• Oosten LEM, Chamuleau MED, Thielen FW, et al. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. Ann Hematol. 2018;97(2):255–266. doi:10.1007/s00277-017-3167-7
   PubMed Web of Science ®Google Scholar
• Chamuleau MED, Stenner F, Chitu Ir DA, et al. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial. Lancet Hematol. 2023. doi:10.1016/S2352-3026(23)00279-X
   PubMedGoogle Scholar
• Kim H, Park ES, Lee SH, et al. Clinical outcome of relapsed or refractory burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescents. Cancer Res Treat. 2014;46(4):358–365. doi:10.4143/crt.2013.047
   PubMed Web of Science ®Google Scholar
• Jourdain A, Auperin A, Minard-Colin V, et al. Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective “Lymphomes Malins B” protocols. A Société Française des Cancers de l’Enfant study. Haematologica. 2015;100(6):810–817. doi:10.3324/haematol.2014.121434
   PubMed Web of Science ®Google Scholar
• Cairo M, Auperin A, Perkins SL, et al. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. Br J Haematol. 2018;182(6):859–869. doi:10.1111/bjh.15491
   PubMed Web of Science ®Google Scholar
• Rigaud C, Auperin A, Jourdain A, et al. Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: a report from the French LMB study. Pediatr Blood Cancer. 2019;66(9):e27873. doi:10.1002/pbc.27873
   PubMed Web of Science ®Google Scholar
• Woessmann W, Zimmermann M, Meinhardt A, et al. Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy. Blood. 2020;135(14):1124–1132. doi:10.1182/blood.2019003591
   PubMed Web of Science ®Google Scholar
• Reutter K, Sandmann S, Rohde J, et al. Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma. Leukemia. 2021;35(2):639–643. doi:10.1038/s41375-020-0862-5
   PubMed Web of Science ®Google Scholar
• Moleti ML, Testi AM, Foà R. Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2020;189(5):826–843. doi:10.1111/bjh.16461
   PubMed Web of Science ®Google Scholar
• Griffin TC, Weitzman S, Weinstein H, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2009;52(2):177–181. doi:10.1002/pbc.21753
   PubMed Web of Science ®Google Scholar
• Osumi T, Mori T, Fujita N, et al. Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatr Blood Cancer. 2016;63(10):1794–1799. doi:10.1002/pbc.26105
   PubMed Web of Science ®Google Scholar
• Atra A, Gerrard M, Hobson R, et al. Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin’s lymphoma treated with the UKCCSG 9003/9002 protocols. Br J Haematol. 2001;112(4):965–968. doi:10.1046/j.1365-2141.2001.02647.x
   PubMed Web of Science ®Google Scholar
• Anoop P, Sankpal S, Stiller C, et al. Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. Leuk Lymphoma. 2012;53(10):1882–1888. doi:10.3109/10428194.2012.677534
   PubMed Web of Science ®Google Scholar
• Maramattom LV, Hari PN, Burns LJ, et al. Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2013;19(2):173–179. doi:10.1016/j.bbmt.2012.11.016
   PubMed Web of Science ®Google Scholar
• Satwani P, Jin Z, Martin PL, et al. Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. Leukemia. 2015;29(2):448–455. doi:10.1038/leu.2014.194
   PubMed Web of Science ®Google Scholar
• Short NJ, Kantarjian HM, Ko H, et al. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017;92(6):E114–E117. doi:10.1002/ajh.24720
   PubMed Web of Science ®Google Scholar
• Burkhardt B, Taj M, Garnier N, et al. Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations. Cancers. 2021;13(9):2075. doi:10.3390/cancers13092075
   PubMed Web of Science ®Google Scholar
• Manji F. Outcomes in Relapsed/Refractory Burkitt Lymphoma: a Multi-Centre Canadian Experience. Blood. 2021;138(Supplement 1):2525. doi:10.1182/blood-2021-146036
   Google Scholar
• Gardenswartz A, Mehta B, El‐Mallawany N, et al. Safety and efficacy of myeloablative conditioning autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B‐cell Non Hodgkin lymphoma. Br J Haematol. 2024;182(Suppl. 1):23.
   Google Scholar
• Sweetenham JW, Pearce R, Taghipour G, et al. Adult Burkitt’s and Burkitt-like non-Hodgkin’s lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol. 1996;14(9):2465–2472. doi:10.1200/JCO.1996.14.9.2465
   PubMed Web of Science ®Google Scholar
• Chen YB, Lane AA, Logan B, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(6):1046–1053. doi:10.1016/j.bbmt.2015.02.005
   PubMed Web of Science ®Google Scholar
• Burke GAA, Vinti L, Kabickova E, et al. Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial. Blood Adv. 2023;7(4):602–610. doi:10.1182/bloodadvances.2022008802
   PubMed Web of Science ®Google Scholar
• Barth MJ, Hochberg J, Harrison L, et al. Phase 2 Trial of Obinutuzumab, a Humanized, Glycoengineered Monoclonal CD20 Antibody, in Combination with Ifosfamide, Carboplatin and Etoposide for Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma. Br J Haematol. 2022;182(Suppl. 1):48–49.
   Google Scholar
• Melani C, Lakhotia R, Pittaluga S, et al. Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: preliminary Analysis of Safety and Efficacy. Blood. 2022;140(Supplement 1):6602–6603.
   Google Scholar
• Poh C, Frankel P, Ruel C, et al. Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin’s Lymphoma: a Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis. Blood. 2019;134(Supplement_1):760.
   Google Scholar
• Minard V, Maude SL, Buechner J, et al. Bianca: Phase II, single-arm, global trial to determine efficacy and safety of tisagenlecleucel in pediatric/young adult (YA) patients (Pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). J clin oncol. 2020;38(15_suppl). doi:10.1200/JCO.2020.38.15_suppl.e22504
   Web of Science ®Google Scholar
• Martínez-Cibrián N, Ortiz-Maldonado V, Español-Rego M, et al. The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2023. doi:10.1111/bjh.19170
   PubMed Web of Science ®Google Scholar
• Liu Y, Deng B, Hu B, et al. Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma. Blood Adv. 2022;6(3):717–730. doi:10.1182/bloodadvances.2021004557
   PubMed Web of Science ®Google Scholar
• Wu J, Cao Y, Zhang Q, et al. Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma. Front Immunol. 2022;13:879983. doi:10.3389/fimmu.2022.879983
   PubMed Web of Science ®Google Scholar
• Strati P, Nastoupil LJ, Davis RE, et al. A Phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica. 2020;105(1):e26–e28. doi:10.3324/haematol.2019.220012
   PubMed Web of Science ®Google Scholar
• Awasthi A, Ayello J, Van de Ven C, et al. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL. Br J Haematol. 2015;171(5):763–775. doi:10.1111/bjh.13764
   PubMed Web of Science ®Google Scholar
• Tiwari AA, Edani T, Ayello J, et al. Blinatumomab enhanced anti-tumor activity against rituximab sensitive and resistant Burkitt Lymphoma (BL) and Primary Mediastinal B-cell Lymphoma (PMBL). Cancer Res. 2019;79(13_Supplement):2381.
   Web of Science ®Google Scholar
• Duell J, Zugmaier G, Eisele F, et al. Treatment of R/R Burkitt Lymphoma with blinatumomab is feasible and induced a long lasting complete remission. HemaSphere. 2019;3(S1):816–817.
   Google Scholar
• Bohler J, Bacher U, Banz Y, et al. Blinatumomab in Relapsed/Refractory Burkitt Lymphoma. Cancers. 2022;15(1):44. doi:10.3390/cancers15010044
   PubMed Web of Science ®Google Scholar
• Zhang W, Yang J, Zhou C, et al. Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells. Blood. 2020;135(26):2425–2427. doi:10.1182/blood.2019002008
   PubMed Web of Science ®Google Scholar
• Samples LS, Sadrzadeh H, Frigault MJ, et al. Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma. J clin oncol. 2023;41(16 suppl):7571.
   Google Scholar
• Doroshow DB, Eder JP, LoRusso PM. BET inhibitors: a novel epigenetic approach. Ann Oncol. 2017;28(8):1776–1787. doi:10.1093/annonc/mdx157
   PubMed Web of Science ®Google Scholar
• Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370):524–528. doi:10.1038/nature10334
   PubMed Web of Science ®Google Scholar
• Wilke AC, Doebele C, Zindel A, et al. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. Blood. 2022;139(4):538–553. doi:10.1182/blood.2021012081
   PubMed Web of Science ®Google Scholar
• Noy A, Pardee TS, Nikolaenko L, et al. A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements of MYC and BCL2 and/or BCL6. Blood. 2019;134(Supplement 1):4087. doi:10.1182/blood-2019-131563
   Google Scholar